Illumina Inc. (NASDAQ:ILMN) Director Daniel Bradbury sold 600 shares of the company’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $136.34, for a total transaction of $81,804.00. Following the transaction, the director now directly owns 17,065 shares of the company’s stock, valued at approximately $2,326,642.10. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Daniel Bradbury also recently made the following trade(s):

  • On Friday, October 7th, Daniel Bradbury sold 600 shares of Illumina stock. The shares were sold at an average price of $184.36, for a total transaction of $110,616.00.
  • On Wednesday, September 14th, Daniel Bradbury sold 600 shares of Illumina stock. The shares were sold at an average price of $171.25, for a total transaction of $102,750.00.

Illumina Inc. (NASDAQ:ILMN) traded down 1.346% on Thursday, reaching $133.055. The company had a trading volume of 738,898 shares. Illumina Inc. has a 12 month low of $127.10 and a 12 month high of $196.47. The company’s 50 day moving average price is $149.50 and its 200-day moving average price is $152.93. The company has a market capitalization of $19545.78 billion, a price-to-earnings ratio of 44.649 and a beta of 1.24.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, November 1st. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.10. The company had revenue of $607 million for the quarter, compared to analyst estimates of $628.06 million. Illumina had a return on equity of 23.76% and a net margin of 18.72%. The business’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.80 earnings per share. On average, equities analysts predict that Illumina Inc. will post $3.32 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

A number of analysts recently issued reports on the stock. Canaccord Genuity set a $136.00 target price on shares of Illumina and gave the stock a “hold” rating in a research report on Friday, October 7th. Vetr downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $187.86 target price for the company. in a research report on Monday, October 10th. Citigroup Inc. downgraded shares of Illumina from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $190.00 to $140.00 in a research report on Tuesday, October 11th. Janney Montgomery Scott downgraded shares of Illumina from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $155.00 to $125.00 in a research report on Tuesday, October 11th. Finally, Cantor Fitzgerald dropped their target price on shares of Illumina from $165.00 to $155.00 and set a “hold” rating for the company in a research report on Tuesday, October 11th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $152.88.

A number of institutional investors have recently bought and sold shares of ILMN. Baillie Gifford & Co. raised its position in Illumina by 3.8% in the second quarter. Baillie Gifford & Co. now owns 18,615,061 shares of the life sciences company’s stock worth $2,613,182,000 after buying an additional 682,010 shares in the last quarter. Capital Research Global Investors raised its position in Illumina by 2.1% in the third quarter. Capital Research Global Investors now owns 13,360,554 shares of the life sciences company’s stock worth $2,427,078,000 after buying an additional 275,483 shares in the last quarter. Vanguard Group Inc. raised its position in Illumina by 2.0% in the second quarter. Vanguard Group Inc. now owns 8,982,784 shares of the life sciences company’s stock worth $1,261,004,000 after buying an additional 178,186 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Illumina by 1.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 3,877,155 shares of the life sciences company’s stock worth $704,324,000 after buying an additional 41,792 shares in the last quarter. Finally, Capital World Investors raised its position in Illumina by 37.1% in the third quarter. Capital World Investors now owns 2,006,100 shares of the life sciences company’s stock worth $364,428,000 after buying an additional 543,100 shares in the last quarter. 93.95% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.